190
Index
C
Caenorhabditis elegans, 66, 171, 172
Carbapenem, 2, 11, 35
Carbavance, 29
Carbon monoxide release, 135
Carrier-linked (carrier) prodrugs, 122
cascade prodrug, 123
double prodrug, 122
macromolecular prodrug, 123
mutual prodrug, 123
site-specific prodrug, 123
Catch and release strategy, 146
Catechol, derivatives, moiety, 68, 86, 99
Catenanes, 71, 166
CDC, USA, 6, 10
Cefepime, 28, 29
Cefiderocol, 85
Ceftibuten, 29, 30
Ceftriaxone, 15, 32, 172
Centaur platform, 166
CepI inhibitors, 171
Chaperones, bacterial, 175
Chaperonins, bacterial, 175
Cilastatin, 35
Ciprofloxacin-naringenin hybrid, 84
Ciprofloxacin-sulfanilamide hybrid, 85
Climacostol, 164
Clostridioides difficile, 6, 10
Clostridium difficile, 6, 9, 61, 83, 137, 150
Combinations, antibacterial, Chapter 2, 21
Community for Open Antimicrobial Drug
Discovery (CoADD), 10
Coptisine, 80
CORMs, 135
Cryo-EM, 160
Crystal violet, 41, 42
Cyclopropanation, 94
D
Darobactin, 176
Deoxy-D-xylulose-5-Phosphate
(DXP)
synthase, 143
DFT calculations, 80
DHFR inhibitors, 26, 61, 62
Diazeniumdiolates, 132
Dicathais orbita, 163
Dihydrofolate Reductase (DHFR), 26, 61,
76, 102
Dihydropteroate synthetase inhibitors, 26,
60
Diketopiperazine inhibitors, 171
1,3-Dipolar cycloaddition, 72, 73, 146
Discuva platform, 167
DNA gyrase, 9, 15, 24, 35, 60, 62, 102
DNA synthesis, inhibition, 98, 124
Drug repurposing, 12
DsbA inhibitors, 169
DXP inhibitors, 143
E
Eagle Effect, 9
Efflux pump inhibitors, 28, 32, 88, 89
Emergent interactions, 34, 35, 43
Enterobacter cloaca, 9
Enterobacteriaceae, 2, 29
Enterobacter species, 3, 9
Enterobactin-ciprofloxacin prodrug, 128
Enterococcus faecium, 3
ENTRyway, web application, 55, 58
Epetraborole, 31
E-Pharmacophore modelling, 167
Escherichia coli, antibacterial synergy, 34,
35, 43
Escherichia coli, aPDT, 38
Escherichia coli, compound accumulation,
55
Escherichia coli, introduction, 6, 8
Escherichia coli, MsbA inhibition, 162
Escherichia coli, MscL, 150
Escherichia coli, prodrug activation, 144
Escherichia coli, quorum sensing inhibition,
66
Esterase, hydrolysis, 29, 123, 141, 145
F
F12, AgrA inhibition, 25
F19, AgrA inhibition, 25
Fidaxomicin, 160
Fimbrolide, analogues, 172
Fimbrolide, hybrid, 135
Flatland, drug design, 92
Fluorosulfate group, 97
Fragment-based design, 56, 68
FtsZ protein, 28, 65, 71
G
G0507, 177
G0775, LepB inhibitor, 174
G592, MsbA transport inhibitor, 162
G907, MsbA transport inhibitor, 162
Gallium (III), 85, 108
Gentian violet, 2, 41
Glutathione, 125, 129
Index
C
Caenorhabditis elegans, 66, 171, 172
Carbapenem, 2, 11, 35
Carbavance, 29
Carbon monoxide release, 135
Carrier-linked (carrier) prodrugs, 122
cascade prodrug, 123
double prodrug, 122
macromolecular prodrug, 123
mutual prodrug, 123
site-specific prodrug, 123
Catch and release strategy, 146
Catechol, derivatives, moiety, 68, 86, 99
Catenanes, 71, 166
CDC, USA, 6, 10
Cefepime, 28, 29
Cefiderocol, 85
Ceftibuten, 29, 30
Ceftriaxone, 15, 32, 172
Centaur platform, 166
CepI inhibitors, 171
Chaperones, bacterial, 175
Chaperonins, bacterial, 175
Cilastatin, 35
Ciprofloxacin-naringenin hybrid, 84
Ciprofloxacin-sulfanilamide hybrid, 85
Climacostol, 164
Clostridioides difficile, 6, 10
Clostridium difficile, 6, 9, 61, 83, 137, 150
Combinations, antibacterial, Chapter 2, 21
Community for Open Antimicrobial Drug
Discovery (CoADD), 10
Coptisine, 80
CORMs, 135
Cryo-EM, 160
Crystal violet, 41, 42
Cyclopropanation, 94
D
Darobactin, 176
Deoxy-D-xylulose-5-Phosphate
(DXP)
synthase, 143
DFT calculations, 80
DHFR inhibitors, 26, 61, 62
Diazeniumdiolates, 132
Dicathais orbita, 163
Dihydrofolate Reductase (DHFR), 26, 61,
76, 102
Dihydropteroate synthetase inhibitors, 26,
60
Diketopiperazine inhibitors, 171
1,3-Dipolar cycloaddition, 72, 73, 146
Discuva platform, 167
DNA gyrase, 9, 15, 24, 35, 60, 62, 102
DNA synthesis, inhibition, 98, 124
Drug repurposing, 12
DsbA inhibitors, 169
DXP inhibitors, 143
E
Eagle Effect, 9
Efflux pump inhibitors, 28, 32, 88, 89
Emergent interactions, 34, 35, 43
Enterobacter cloaca, 9
Enterobacteriaceae, 2, 29
Enterobacter species, 3, 9
Enterobactin-ciprofloxacin prodrug, 128
Enterococcus faecium, 3
ENTRyway, web application, 55, 58
Epetraborole, 31
E-Pharmacophore modelling, 167
Escherichia coli, antibacterial synergy, 34,
35, 43
Escherichia coli, aPDT, 38
Escherichia coli, compound accumulation,
55
Escherichia coli, introduction, 6, 8
Escherichia coli, MsbA inhibition, 162
Escherichia coli, MscL, 150
Escherichia coli, prodrug activation, 144
Escherichia coli, quorum sensing inhibition,
66
Esterase, hydrolysis, 29, 123, 141, 145
F
F12, AgrA inhibition, 25
F19, AgrA inhibition, 25
Fidaxomicin, 160
Fimbrolide, analogues, 172
Fimbrolide, hybrid, 135
Flatland, drug design, 92
Fluorosulfate group, 97
Fragment-based design, 56, 68
FtsZ protein, 28, 65, 71
G
G0507, 177
G0775, LepB inhibitor, 174
G592, MsbA transport inhibitor, 162
G907, MsbA transport inhibitor, 162
Gallium (III), 85, 108
Gentian violet, 2, 41
Glutathione, 125, 129